纳米药物应用于肿瘤免疫全周期

（图片源于：Nat Rev Immunol 2017;17:97–111.）

图片源于文献5

喵评：纳米药物通过表面靶向抗体，同时调节理化性质，增加其靶向提送药物及缓释的能力。避免传统药物递送的系统毒性，增加肿瘤局部的药物浓度，具有其独到的特点。结合经典的抗肿瘤药物及抗体药物，可应用于整个肿瘤免疫周期。

主要参考文献

1. Milhem, M. M. et al. Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy. J. Clin. Oncol. 37, 9534 (2019).

2. Nuhn, L. et al. Nanoparticle-conjugate TLR7/8 agonist localized immunotherapy provokes safe antitumoral responses. Adv. Mater. 30, 1803397 (2018).

3. Yuan, H. et al. Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy. Nat. Nanotechnol. 12, 763–769 (2017).

4. Long, G. V. et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/ KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 20, 1083–1097 (2019).

5. Cheng, K. et al. Sequentially responsive therapeutic peptide assembling nanoparticles for dual-targeted cancer immunotherapy. Nano Lett. 18, 3250–3258 (2018).

6. John D. Martin，et al，Improving cancer immunotherapy using nanomedicines: progress,  opportunities and challenges，Nat Rev Clin Oncol . 2020 Apr;17(4):251-266.